This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

One of the most agonizing experiences a cancer patient suffers is waiting without knowing: waiting for a diagnosis, waiting ...

The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...

Interior Design Show returned in late January to the 180,000-square-foot North Building of the Metro Toronto Convention ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) fell 21% today, diverging from the company's recent ...

If Florida Republicans are looking for a smooth transition from DeSantis to whoever comes next, they've likely misjudged the ...

Hypothetical devices that can quickly and accurately answer questions have become a powerful tool in computational complexity theory.

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Physics is the search for and application of rules that can help us understand and predict the world around us. Central to physics are ideas such as energy, mass, particles and waves. Physics ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

The current human tissue-based study provides compelling evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.